SNY Jan 2024 45.000 call
| Previous close | 1.9500 |
| Open | 2.1500 |
| Bid | 1.6000 |
| Ask | 3.8000 |
| Strike | 45.00 |
| Expiry date | 2024-01-19 |
| Day's range | 2.1500 - 2.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 213 |
- Reuters
UPDATE 2-US urges makers of infant RSV shots to meet winter demand
U.S. officials met with manufacturers of the infant and toddler RSV immunization Beyfortus this week seeking to boost access to the shot, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week. The officials on Tuesday met with representatives of Sanofi , AstraZeneca and Thermo Fisher "and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market," the White House said in a statement.
ZacksSanofi (SNY) Posts Upbeat Long-Term Outlook, Enhances R&D Focus
Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immunology.
- Reuters
US urges RSV vaccine makers to meet winter demand, White House says
U.S. officials met again with RSV vaccine manufacturers this week amid ongoing efforts to boost access to the shots, the White House said in a statement on Thursday after senior Biden administration officials met with the companies last week. The officials on Tuesday met with representatives of Sanofi SA, AstraZeneca and Thermo Fisher "and urged them to work expeditiously to meet demand for immunizations this winter season through the commercial market," the White House said in a statement.
